Roivant CFO Richard Pulik Sells $12.47 Million of Stock After Option Exercise
Roivant Sciences Chief Financial Officer Richard Pulik sold $12.47 million of the company's stock this week after exercising stock options, according to a Form 4 filed Thursday.
Pulik exercised fully vested options on 125,000 common shares on Nov. 10 and 127,365 shares on Nov. 11, each at an exercise price of $3.85, the filing shows. Across the two days he sold 300,000 shares at weighted average prices from $41.20 to $42.03.
The sales came to $12,473,272. Footnotes say the shares were sold in multiple transactions at prices ranging from $40.88 to $42.14.
Pulik's holdings
Pulik directly held 222,046 Roivant common shares after the last sale, according to the Form 4. The Form 4 does not indicate that the sales were made under a Rule 10b5-1 trading plan.
A second executive sale
In a separate Form 4 filed the same evening, Eric Venker, listed as President and Immunovant CEO, reported selling 187,943 Roivant shares on Nov. 10 at weighted average prices of $40.44 and $41.00, for $7,617,074. He directly held 811,211 shares afterward.
Venker's filing indicates the sales were made under a Rule 10b5-1 trading plan.
By the numbers
- Pulik options exercised: 252,365 at $3.85
- Pulik shares sold: 300,000 for $12,473,272
- Pulik direct holdings afterward: 222,046 shares
- Venker shares sold: 187,943 for $7,617,074
- Venker direct holdings afterward: 811,211 shares
Sources
- Form 4, Richard Pulik, Roivant Sciences Ltd., filed Nov. 12, 2026, accession 0001635088-26-000139
- Form 4, Eric Venker, Roivant Sciences Ltd., filed Nov. 12, 2026, accession 0001635088-26-000137
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence. SI may make mistakes.